Innoviva (INVA) Capital Expenditures Growth (3y) (2013 - 2026)
Innoviva (INVA) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 16.27% |
| 10 | Innoviva | 1.60 Bn | 995.80 Mn | 75.83 Mn | 146.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.12% |
| Sep 30, 2025 | 223.86% |
| Mar 31, 2023 | 36.41% |
| Dec 31, 2019 | -24.61% |
| Dec 31, 2016 | -70.28% |
| Sep 30, 2016 | 0.84% |
| Jun 30, 2016 | -77.38% |
| Dec 31, 2015 | -84.35% |
| Mar 31, 2015 | -82.41% |
| Dec 31, 2014 | -47.23% |
| Jun 30, 2014 | -40.44% |
| Mar 31, 2014 | 5.46% |
| Dec 31, 2013 | 22.88% |
| Sep 30, 2013 | 15.54% |